Publications by authors named "Philipp Rassek"
Article Synopsis
- The study aimed to compare interim PSMA-PET imaging with post-treatment whole-body scans (WBS) in monitoring treatment response for men with metastasized castration-resistant prostate cancer (mCRPC) undergoing radioligand therapy (RLT).
- Researchers included 188 men and found a strong correlation between responses measured by the two imaging methods, indicating that both affect overall survival (OS) outcomes significantly.
- Results suggested that early treatment responses, particularly a PSA decline of 50% after two cycles, were associated with improved survival probabilities, highlighting the importance of interim imaging in therapy monitoring.
Article Synopsis
- This study investigates if a PSMA-PET scan from the skull base to proximal thigh is sufficient for detecting bone metastases in prostate cancer patients.
- A retrospective analysis of 1050 PET scans revealed significant correlations between PSA levels and the presence of bone metastases, identifying that most metastases occur in patients with higher numbers of total metastases.
- The study concludes that specific PSA cut-off values (11.15 ng/mL for below the thigh and 12.86 ng/mL for above the skull base) can effectively indicate the presence of bone metastases, showcasing the potential for optimized imaging strategies.
Ra-dichloride (Ra) and Lu-prostate-specific membrane antigen (PSMA) are approved treatments for metastatic castration-resistant prostate cancer (mCRPC). The safety and effectiveness of sequential use of Ra and Lu-PSMA in patients with mCRPC are not well described. This study aimed to evaluate Lu-PSMA safety and efficacy in patients with mCRPC previously treated with Ra.
View Article and Find Full Text PDFPurpose: Prostate-specific membrane antigen (PSMA) is present in the proximal tubule cells of the kidneys. This results in high renal tracer uptake in PSMA-PET, which may contain useful information on renal function. As part of the evaluation for [Lu]-PSMA therapies, patients undergo PSMA-PET and additional [Tc]-mercapto-acetyltriglycine (MAG3) scintigraphy to assess renal function.
View Article and Find Full Text PDFThe apparent diffusion coefficient (ADC) is a candidate marker of treatment response in osteoblastic metastases that are not evaluable by morphologic imaging. However, it is unclear whether the ADC meets the basic requirement for reliable treatment response evaluation, namely a low variance of repeated measurements in relation to the differences found between viable and nonviable metastases. The present study addresses this question by analyzing repeated in vivo ADC measurements of 65 osteoblastic metastases in nine patients, as well as phantom measurements.
View Article and Find Full Text PDFThe radium lutetium (RALU) study evaluated the feasibility of sequential α- and β-emitter use in patients with bone-predominant metastatic castration-resistant prostate cancer. This preplanned interim retrospective analysis investigated safety and survival outcomes with Lu-PSMA in patients treated with prior Ra. Forty-nine patients were evaluated.
View Article and Find Full Text PDF